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Abstract. The identification of mutations in FGFR3 in bladder tumors in 1999 led to major interest in this receptor and
during the subsequent 20 years much has been learnt about the mutational profiles found in bladder cancer, the phenotypes
associated with these and the potential of this mutated protein as a target for therapy. Based on mutational and expression
data, it is estimated that >80% of non-muscle-invasive bladder cancers (NMIBC) and ∼40% of muscle-invasive bladder
cancers (MIBC) have upregulated FGFR3 signalling, and these frequencies are likely to be even higher if alternative splicing
of the receptor, expression of ligands and changes in regulatory mechanisms are taken into account. Major efforts by the
pharmaceutical industry have led to development of a range of agents targeting FGFR3 and other FGF receptors. Several of
these have entered clinical trials, and some have presented very encouraging early results in advanced bladder cancer. Recent
reviews have summarised the drugs and related clinical trials in this area. This review will summarise what is known about
the effects of FGFR3 and its mutant forms in normal urothelium and bladder tumors, will suggest when and how this protein
contributes to urothelial cancer pathogenesis and will highlight areas that may benefit from further study.
FGFR3 STRUCTURE AND ACTIVATION
FGF receptors are transmembrane receptor tyro-
sine kinases consisting of three extracellular
immunoglobulin (Ig) domains, a single-pass trans-
membrane domain and an intracellular split kinase
domain (Fig. 1A). There are four full-length receptors
that conform to this structure (FGFRs 1–4). A fifth
receptor (FGFRL1) lacks the intracellular domain
and is thought to antagonise FGFR signalling by
acting as a decoy receptor [6]. There are 22 known
human fibroblast growth factors (FGFs), 18 of which
are secreted and interact with FGFRs [7]. These
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bind to the extracellular domain of the receptor, with
differential ligand-binding specificity determined by
alternative splicing of FGFRs in Ig domain III.
Although there are only 4 FGFRs, alternative splic-
ing and the large number of FGFs provide highly
variable signalling potential. In FGFR3, alternative
inclusion of exons 8 or 9 generates isoforms 3b and
3c respectively (Fig. 1A). FGFs in the extracellular
matrix interact with heparan sulphate proteoglycans
(HSPGs) and binding of HSPGs by FGFRs helps to
stabilise the ligand-receptor interaction. FGFR3-3b,
expression of which is confined to normal epithe-
lial tissues, binds FGF1 strongly and FGFs 9, 16
and 20 with weaker affinity, whereas FGFR3-3c can
bind FGF2 and many more FGFs [8]. Binding of
an FGF to a monomeric FGFR induces receptor
dimerization, autophosphorylation of multiple tyro-
sine residues in the kinase domain and activation
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of downstream signalling pathways [9]. The acti-
vated receptor binds and phosphorylates FRS2 which
recruits GRB2 and SOS to activate the RAS/MAPK
pathway [10]. Phosphorylation of GAB1 leads to
recruitment and activation of phosphatidylinositol 3-
kinase (PI3K) [11], and PLC binding to FGFR3
independently of FRS2 leads to activation of pro-
tein kinase C [12]. Activation of STAT [13, 14] and
RSK2 [15] can also occur. Signalling output, which
is highly dependent on cell context, can lead to a
range of changes including proliferation, migration
and differentiation [7].
FGFR3 EXPRESSION IN THE NORMAL
UROTHELIUM AND CULTURED
NORMAL UROTHELIAL CELLS
In human urothelium, FGFR3 is the most abun-
dantly expressed FGF receptor at both mRNA and
protein levels [16, 17]. Normal human urothelial cells
are highly proliferative in culture and can be main-
tained for multiple passages before senescence [18].
During this finite lifespan, FGFR3 mRNA and protein
levels increase when cells are proliferatively quies-
cent at confluence and there is a major increase in
expression as cells approach senescence [16]. These
findings in normal urothelial cells provide clues that
regulation of FGFR3 may be linked to urothelial con-
tact inhibition and/or senescence.
The 3b isoform is the predominant full length
mRNA FGFR3 isoform in normal urothelial cells.
However, an isoform lacking exons 8–10 (8–10)
was found to dominate in cultured normal cells and,
like the full length form, is upregulated at confluence.
This isoform, which lacks the region encoding the
second part of the third Ig-like loop and the trans-
membrane domain, is translated, glycosylated and
secreted. It can bind FGF1 and dimerise, and was able
to block the response to FGF1 in cells expressing full-
length FGFR3. As 8–10 is expressed at lower levels
in tumor cell lines, this implies that by binding and
sequestering FGFs, or by binding and inhibiting sig-
nalling by the full-length receptor, this isoform may
perform an important negative regulatory role in the
normal urothelium [16].
ABERRANT ACTIVATION OF FGFR3 IN
BLADDER CANCER
Alterations affecting FGFR3 signalling are found
more frequently in bladder than in any other cancer
type. Aberrant activation of the receptor can occur via
several mechanisms. These are related to tumor stage
and grade, and have different effects on downstream
signalling and phenotypic consequences. Such aber-
rant activation may occur at different stages during
the pathogenesis of NMIBC and MIBC and may
cooperate with other events in a context-dependent
manner.
FGFR3 point mutation
The first and most common mechanism of activa-
tion is missense point mutation [1, 19–24]. Mutations
are located in several hotspots in the protein (Fig. 1A).
By far the most common (63% of reported mutations)
is S249C, followed by Y375C, these two mutations
accounting for >80% of all mutations detected. These
point mutations show a strong relationship to low
tumor grade and stage [25]. Up to 85% of papil-
lary urothelial neoplasms of low malignant potential
(PUNLMP) and stage Ta tumors have a mutation,
stage T1 tumors have lower frequency (∼20–40%)
and MIBC lower still (12–15%) [17, 19, 20, 26–31].
When present in the germline, the common muta-
tions found in bladder cancer cause severe, autosomal
dominant and lethal forms of skeletal dysplasia.
R248C, S249C, G370/372C and Y373/375C (3c/3b
isoform numbering) cause thanatophoric dyspla-
sia type I (TDI), and the kinase domain mutation
K650/652E causes thanatophoric dysplasia type II
(TDII) [32]. In this context, FGFR3 activation leads to
premature cessation of proliferation of chondrocytes
in the long bone growth plates [33].
Mutations resulting in replacement with a cys-
teine residue were assumed to cause formation of
a disulphide bond leading to constitutive receptor
activation. These mutant forms do indeed lead to
constitutive receptor phosphorylation and ligand-
independence [34], though when the strength of the
dimers formed was measured by Förster resonance
energy transfer (FRET) it was found to be relatively
modest, suggesting that other structural perturbations
in the dimer may contribute to the strong down-
stream signalling induced by these mutant forms [35].
In contrast, the K650/652E mutant form exists as
a ligand-independent constitutively phosphorylated
monomer [34, 36], and G380/382R and A391/393E
remain predominantly ligand-dependent for activa-
tion [37, 38].
Although S249C is the most common mutation
found in bladder cancer, R248C is much more
common in the germline. These mutations are also
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Fig. 1. FGFR3 point mutations and translocations in bladder cancer. A. Structure of FGFR3 isoform 3b protein showing position of point
mutations. Mutation data taken from tumors of all grades and stages (COSMIC, June 2020). IgI, IgII, IgIII: immunoglobulin-like domains.
AB: acid box. TK1 and TK2: split tyrosine kinase domain. 3b/3c: region of exons 8 and 9 where alternative splicing generates isoforms
3b and 3c. B. Examples of FGFR3 fusion proteins identified in bladder tumors. TACC: transforming acid coiled-coil. IMD: IRDp53/MIM
homology. SH3: src homology.
found in the benign skin lesions seborrheic kerato-
sis and epidermal nevi where, as in the germline,
R248C is the more common mutation [39]. What
determines the difference in prevalence in these situa-
tions? Several factors might contribute; there may be
differential tolerance of certain mutations in the entire
organism versus specific somatic tissues, somatic
selection pressures may select for one rather than
the other depending on context-dependent function,
or the mutational processes at work may differ. An
elegant study recently examined the relationship of
S249C mutations and APOBEC-mediated mutage-
nesis in bladder cancer [40]. A large proportion
of both NMIBC and MIBC have elevated expres-
sion of APOBEC enzymes and their mutational
profiles contain a high load of predicted APOBEC-
mediated mutational events [30, 41]. Of all FGFR3
point mutations found in bladder cancer, only S249C
(TCC > TGC) shows similarity to an APOBEC-type
mutation (TCN > T[G/T]N) where N is usually A or
T. When the distribution of S249C mutations was
related to APOBEC mutational load, a clear rela-
tionship was found in both NMIBC and MIBC [40].
APOBEC mutagenesis preferentially targets lagging
strand ssDNA templates and it was shown that the
coding strand of FGFR3 is mainly replicated as a
lagging strand. The sequence context of S249 is
predicted to allow a hairpin structure to form, also
favoured by APOBEC enzymes. This study also
demonstrated that the S249 codon sequence can
be deaminated by APOBEC3A, providing a highly
persuasive explanation for the excess of S249C muta-
tions in bladder tumors. The differential mutation
frequency in tumors of different stages, despite higher
APOBEC activity in MIBC, likely reflects distinct
pathogenesis pathways of these tumor groups.
Whether there are any differences in the selec-
tive advantage of the two most common mutations is
not entirely clear. Although the most common muta-
tions, S249C and Y375C, have similar oncogenic
potency in immortal mesenchymal cells [40, 42], it
is not certain that both confer the same advantage
in urothelial cells. Knockdown of FGFR3 in bladder
tumor cell lines bearing these mutations was shown
to have similar transcriptional effects [40]. However,
in cultured telomerase-immortalized normal urothe-
lial cells (TERT-NHUC), a difference in the potency
of these mutations has been found. Both mutations
drive cells to a higher cell density at confluence,
but S249C has the more potent effect [42]. Y375C
is less strongly dimerised and retains some ligand
dependence, suggesting that it may rely on stromal
or autocrine ligand for maximal effect. Whether lig-
ands are available in vivo at the time of receptor
mutation is currently unknown. Thus S249C pre-
dominance can be explained as both APOBEC target
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and possibly in provision of a more potent selective
advantage.
The strength of the phenotype of increased prolifer-
ation and cell viability at confluence in TERT-NHUC
expressing point mutant forms of FGFR3 is in
the order of mutation frequency found in tumors
(S249C>Y375C>K652E) despite the fact that K652E
is the most highly phosphorylated form in these cells
[42]. This lack of contact inhibition was reflected
in changes in cell-cell and cell-substrate adhesion,
with the appearance of looser cell-cell junctions in
cells expressing S249C- and Y375C-FGFR3 com-
pared to controls and cells expressing high levels
of wildtype FGFR3 [43]. The cells detached more
readily from culture vessels coated with collagen
IV, collagen I and fibronectin, and changes in
expression of genes involved in mediating cell-cell
and cell-substrate adhesion and extracellular matrix
remodelling were found. This included downreg-
ulation of EPCAM and genes encoding structural
components of desmosomes (DSC2, DSC3, DSG1,
PKP1, PKP3), adherens junctions (CDH1, CDH16)
and focal adhesions (PXN, ZYX) and upregulation of
several integrins (ITGA2, ITGAV, ITGB5, ITGB6)
and genes involved in extracellular matrix remod-
elling (HAS3, PLAT, PLAU, PLAUR, MMP10).
Several of these genes were conversely altered when
S249C-FGFR3 was knocked down in a mutant tumor
cell line [43]. MMP10 has previously been identified
as an easily-accessible pharmacodynamic biomarker
for FGFR-targeted therapy in bladder cancer. It was
also downregulated when FGFR3 was silenced, and
both MMP1 and MMP10 levels were reduced in
the urine of bladder cancer patients in a phase I
trial of anti-FGFR3 monoclonal antibody [44]. Taken
together, these data indicate that mutant FGFR3 has
effects on regulation of the cell cycle in response to
cell-cell contact, elicits changes in cell junctions and
cell adherence to proteins found in the urothelial base-
ment membrane and adjacent connective tissue [45],
and induces changes in expression of potent modula-
tors of the extracellular matrix, all functions predicted
to provide a selective advantage to cells early in the
process of tumor development.
FGFR3 fusion proteins
FGFR3 can also be activated by the generation of
fusion proteins. These were initially identified when
aberrant high molecular weight forms of FGFR3 were
detected in cell lines and tumors [46]. Such fusions
have subsequently been found in 2–6% of MIBC [30,
31, 47–49]. FGFR3-TACC3 and FGFR3-BAIAP2L1
chimeric proteins have been identified, with FGFR3-
TACC3 fusions appearing most common. Activating
point mutations have not been found in these fusions.
NMIBC have not been examined, though the very
high frequency of point mutations in Ta tumors sug-
gests that any fusions are likely to be found in T1
cases.
All of the fusions described to date contain the
entire sequence of FGFR3 apart from the final exon
(amino acids 1–760) fused to C-terminal regions of
the fusion partner. Examples are shown in Fig. 1B.
TACC3 lies 48 kb telomeric to FGFR3 on chro-
mosome arm 4p and the common mechanism of
fusion is tandem duplication and insertion so that
the coiled-coil region of TACC3 is fused in-frame
to FGFR3 exon 18. As a result of this mechanism,
low-level gain of the region is detected in cases with
translocation.
These fusion proteins show some constitutive
dimerization and are constitutively phosphorylated,
though they do retain some ligand-dependence [46,
50], and they are potently transforming in immor-
tal rodent mesenchymal cells [46, 48]. The fusion
partners are predicted to induce dimerization, as the
coiled-coil domain of TACC3 is retained almost intact
in all FGFR3-TACC3 fusions and the IMD domain,
related to the BAR (Bin-Amphiphysin-Rvs) domain
which can also promote dimerization, is retained in
FGFR3-BAIAP2L1. As BAR domains are predicted
to interact with membranes [51], FGFR3-BAIAP2L1
may show altered cellular localisation. Early experi-
ments in glioblastoma, where similar FGFR3-TACC3
fusions are found, indicated increased aneuploidy
when FGFR3-TACC3 was expressed [52]. TACC3
normally provides stability to the mitotic spindle
and altered levels of expression are associated with
changes in mitotic progression and chromosome seg-
regation [53]. As FGFR3-TACC3 could be detected
at the spindle poles, it was proposed that this directly
caused defects in chromosome segregation [52].
However, the majority of FGFR3-TACC3 fusions
lack TACC3 Ser558, phosphorylation of which is
required for formation of the TACC3-clathrin-ch-
TOG complex at the spindle [54]. More recently,
it has been shown that the fusion protein recruits
wildtype TACC3 away from the spindle and this
was demonstrated in bladder tumor cell lines RT112
and RT4, which contain FGFR3-TACC3 fusions with
different TACC3 components. The effect could be
induced by the TACC3 part of the fusion protein alone
and could be rescued by low-level overexpression of
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wildtype TACC3. Inhibition of the kinase activity of
the fusion protein with the FGFR inhibitor PD173074
did not abrogate the mitotic defects, clearly indicat-
ing a role for the fusion partner component alone [55].
Thus the contribution of the FGFR3-TACC3 fusion
proteins to the neoplastic phenotype comprises not
only FGFR3 kinase-regulated functions but also a
contribution to genomic instability via the TACC3
component.
Upregulated expression and isoform switching
Precise regulation of expression of appropriate
FGFR3 isoform and ligands is required for normal
physiological processes. Studies of protein expres-
sion by immunohistochemistry in stage Ta and
T1 bladder tumors show upregulated expression of
FGFR3 in 70–80% of Ta and 40–70% of T1 tumors
[17, 56–59]. In Ta tumors this directly relates to muta-
tion frequency but in T1 tumors exceeds the known
mutation frequency and indicates likely upregula-
tion of wildtype protein. Although activating point
mutations in FGFR3 are relatively uncommon in
MIBC, upregulated expression of the protein is found
in 30–50% of cases [17, 59–62], though high-level
amplification has not been reported. Whilst a few
of the tumors expressing high levels might contain
fusion genes, the majority are likely to be wild-
type. Figure 2 shows the relationship of expression
to mutation status in relation to tumor stage in a
one-year cohort of tumors diagnosed at a single
Institution [17]. Studies that have examined expres-
sion in matched tumor and lymph node metastases
[60–62] have found good concordance, suggesting
that upregulated FGFR3, particularly if related to
FGFR3 mutation, could be a valid therapeutic tar-
get in such cases. However, some evidence suggests
that upregulated expression in the absence of muta-
tion may not denote FGFR3-dependence. Thus it
is notable that upregulated expression in FGFR3
wildtype tumors in a series of patients treated by
cystectomy was not associated with prognosis in the
same way as mutation [63] and in a trial of Dovitinib
(a multi-kinase inhibitor that inhibits FGFRs 1–3) in
BCG-unresponsive NMIBC, complete responses at 6
months were only observed in patients with mutant
and not over-expressing wildtype tumors [64].
In bladder tumor cell lines, expression of FGFR3
was found to be restricted to those that also expressed
E-cadherin and TP63, both of which are “epithelial”
characteristics, whereas cell lines expressing ZEB1
and vimentin, features of epithelial-mesenchymal
transition (EMT), expressed FGFR1 rather than
FGFR3. Compatible with the relationship of FGFR1
to the EMT phenotype, inhibition of FGFR1 led to
decreased invasion in these cell lines [65]. In bladder
tumor cell lines with epithelial phenotype, ectopic
expression of FGFR1 and treatment with FGF2 can
elicit an EMT [66], suggesting that there are highly
distinct roles for these two receptors in bladder can-
cer. This is supported by studies of bladder tumors,
where a non-overlapping pattern of mRNA expres-
sion of FGFR3 and FGF2, a potent ligand for FGFR1,
is found, with FGF2-expressing tumors showing
EMT characteristics [67]. As expected, at the pro-
tein level FGFR1 is upregulated in tumors of higher
grade and stage, in which FGFR3 mutations are less
common [68, 69]. However, the relative expression
of FGFR1 and FGFR3 has not been examined sys-
tematically in a large tumor series.
In addition to changes in expression level, isoform
switching to the 3c isoform, which binds a wide range
of FGFs, is also predicted to play a role, potentially
facilitating autocrine or paracrine signalling. This has
been identified in MIBC-derived tumor cell lines [16]
but has not been examined in tumor tissues. How-
ever, upregulated expression of FGF2 is common in
advanced bladder tumors [67, 70, 71] and increased
levels of FGF1 and FGF2 can be detected in the urine
of bladder cancer patients [72–75]. Increased levels
of FGFs 19, 21 and 23, all of which bind FGFR3-3c,
have been reported in the serum of patients with blad-
der cancer [76], though the full repertoire of FGFs
that bind FGFR3-3c remains to be examined in tumor
tissues.
REGULATION OF FGFR3 EXPRESSION
As indicated above, although expression of FGFR3
mRNA and protein is strongly related to mutation sta-
tus in NMIBC [17, 19, 22, 29, 77, 78], this is not the
case in MIBC (Fig. 2). Understanding the mechanism
for this upregulation, and of any differential signifi-
cance of mutant versus upregulated wildtype FGFR3,
is of clinical interest, particularly in MIBC where
FGFR3 inhibitor therapy may be used. As ampli-
fication of the FGFR3 region on 4p has not been
identified and low-level gains are uncommon, other
mechanisms of upregulation must exist.
Several transcriptional regulators have been impli-
cated, though their relative importance in the normal
urothelium and in specific tumor settings has not yet
been explored in detail. The p53 family members p63
and p73 have been shown to regulate FGFR3 [79].
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Fig. 2. Mutation and expression of FGFR3 in relation to tumor stage in a one-year cohort of tumors from a single Institution. A. Distribution
of activating point mutations according to tumor stage. B. Expression of FGFR3 protein according to tumor stage. “High” denotes expression
above that found in normal urothelium and “Low” absence of expression or levels lower than in normal urothelium. Data from [17].
p63 is expressed from two promoters to give rise
to two major isoforms, Transcriptionally Active p63
(TAp63) with a transactivation domain at the N ter-
minus and Np63 which has an activation domain at
the C terminus. p63 is expressed in basal and interme-
diate layers of the normal urothelium and is required
for urothelial differentiation [80, 81]. Np63 has
been shown to inhibit EMT [82]. Levels of Np63
are upregulated in low-grade tumors [83] and mir-
ror FGFR3 mutation in distribution. Overall, loss
of expression is a poor prognostic feature [80, 81,
84–87], with most invasive tumors apart from a subset
of aggressive tumors with squamous differentiation
showing low expression [88, 89].
Analysis of cell cycle regulators in a panel of
FGFR-addicted cell lines including urothelial lines,
identified MYC as a critical determinant of FGFR
inhibitor sensitivity and response, and FGFR inhi-
bition in sensitive cell lines led to phosphorylation
and subsequent degradation of MYC by the protea-
some. The importance of MYC in sustaining the
effects of FGFRs was confirmed by inhibition of
MYC expression with the BET inhibitor JQ1 which
recapitulated the effect of FGFR inhibition [90]. A
second study of the relationship of FGFR3 and MYC
in FGFR3-driven bladder tumor cells [91], identi-
fied an FGFR3/MYC positive feedback loop whereby
activated FGFR3 regulates MYC mRNA and pro-
tein levels via p38 and AKT and in turn MYC
directly upregulates FGFR3 by binding to upstream
enhancers. Disruption of this feedback loop though
FGFR, p38, AKT or MYC inhibition was demon-
strated. Importantly, whilst inhibition of FGFRs and
the related phosphorylation of the adaptor protein
FRS2 was independent of response outcome, down-
regulation of MYC in response to FGFR inhibition
predicted response [90]. These findings present not
only potential for therapy but a biomarker for FGFR3
dependence that may be applied in early assessment
of treatment response and/or development of resis-
tance.
FGFR3 expression is also regulated at the mRNA
level by micro RNAs miR-99a/100, both of which
are downregulated in low-grade NMIBC compared
to normal urothelium. These miRs were shown to
downregulate FGFR3 expression in cultured normal
urothelial cells [92] and also to regulate the urothe-
lial differentiation factor FOXA1 [93]. Loss of the
3’ end of FGFR3 containing the target sequence
for these miRs in the FGFR3-TACC3 fusion tran-
script, is compatible with the high-level expression
of these fusion transcripts [50]. As loss of expres-
sion of miRs-99a/100 was almost ubiquitous, and
more frequent than FGFR3 mutation in low-grade
tumors, and the presence of the S249C mutation
was not associated with differential miR expression,
it was suggested that altered miR expression may
lead to FGFR3 upregulation before the acquisition
of mutation in NMIBC [92]. It has been reported
that under hypoxic conditions FGFR3 mRNA and
protein is upregulated in a HIF1-dependent man-
ner in bladder tumor cell lines, whilst miR-100 is
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downregulated [94]. As developing papillary blad-
der tumors have a strongly hypoxic periphery, this
may indicate that hypoxia could be an early mech-
anism by which FGFR3 expression is upregulated
via changes in miR expression prior to acquisition of
mutation.
In MIBC, expression of miRs 99a/100 is lowest
in the luminal-papillary mRNA expression subtype
(see below), where FGFR3 mutations are most com-
mon [30]. Upregulation of wildtype FGFR3 protein
in other MIBC subtypes is unlikely to be regulated
in the same way. Here, levels may be more strongly
regulated by MYC, possibly related to common gain
of 8q in MIBC. Although the predicted relationship
of MYC and FGFR3 mRNA levels could be found
in FGFR3-mutant tumor samples, this did not apply
to FGFR3 wildtype tumors [91]. Indeed, overall lev-
els of MYC expression in MIBC are highest in the
basal/squamous subtype and not in groups with high
frequency of FGFR3 mutation [95].
It has been shown that the position of mutations in
FGFR3 has differential effects on phosphorylation,
retention at the plasma membrane and ubiquitylation
of the receptor, with presumed effects on dura-
tion of signalling. Thus, mutations such as R248C
and Y373/375C, which form dimers at the cell sur-
face, show reduced internalisation compared to the
wildtype receptor [96] and G380/382R, which is
ligand-dependent, is also retained at the membrane
and escapes ligand-mediated internalisation even at
saturating ligand concentrations [37].
FGFR3 SIGNALLING IN NORMAL AND
TUMOR-DERIVED UROTHELIA
Whilst inhibition or knockdown of FGFR3 in cells
containing point mutant or fusion proteins inhibits
cell proliferation e.g.[97–102], cell cycle arrest rather
than apoptosis is induced [100], and escape from
inhibition can occur relatively rapidly [103, 104].
Thus, there is much interest in understanding the
downstream effects of FGFR3 in order to identify
combinatorial or second line approaches that can
enhance the effects of FGFR inhibition and/or prevent
the development of resistance.
Key to understanding how FGFR3 contributes to
bladder cancer development is the critical role of
cellular context in determining its signalling out-
put. This is exemplified by the differential effect
of point mutant forms on chondrocyte proliferation
and in epithelial cancers [42, 105–107]. Signalling
downstream of FGFR3 via RAS/MAPK, PI3K-AKT,
PLC and STATs has been reported in chondrocytes
and other non-epithelial cell types and malignan-
cies such as multiple myeloma where FGFR3 is
upregulated following a translocation event involv-
ing the immunoglobin heavy chain [15, 108–110].
Many studies using chondrocytes or immortalised
mesenchymal cells have focussed on the K650/652E
mutant form. An early study of the tyrosine phos-
phorylation sites in the receptor, and their relative
importance for subsequent phenotypic and signalling
effects, used the 3c isoform, its K650E derivative and
assays in NIH-3T3 cells [13]. In this system STAT1/3
activation was shown to be a major consequence of
FGFR3 activation [14]. Whether phosphorylation of
these sites has similar consequences in urothelial cells
is unknown.
In TERT-NHUC, RAS/MAPK and PLC sig-
nalling are activated following FGF1 stimulation of
ectopically expressed wildtype FGFR3-3b. This con-
trasts with the situation in NIH-3T3 where there is
strong additional activation of the PI3K pathway and
src [42]. In these normal cells, MAPK and PLC
signalling are also activated following ectopic expres-
sion of mutant forms of FGFR3, with no changes in
the levels of activated p38, JNK, SRC, STAT1 and
AKT [42]. In tumor cells, the situation is less clear. It
cannot be assumed that the same pathways are acti-
vated as in normal urothelial cells and it is likely
that responses depend on the availability of dock-
ing and effector proteins and the overall mutational
and expression landscape. In FGFR3-altered blad-
der tumor cell lines, the MAPK pathway is active
downstream of FGFR3 as demonstrated by major
inhibition of p-ERK but not p-AKT following FGFR
inhibitor treatment [103, 111]. This preferential acti-
vation of the MAPK pathway in urothelial cells
provides a rationale for the finding that FGFR3 and
RAS gene mutations are mutually exclusive in blad-
der tumors [112]. However, dominance of the MAPK
pathway has not been confirmed by assessment of
pathway activation status in tumor tissues. Indeed,
p-AKT rather than p-ERK detected by immunohisto-
chemistry was reported to be associated with FGFR3
mutation [113]. Possibly both pathways are activated
in the majority of tumors. Plasticity in signalling via
these pathways is now well-documented and is exem-
plified in cell lines by resistance to or escape from
FGFR3 inhibition in RT112 via PI3K/AKT signalling
[111, 114]. Maintenance of MAPK pathway activity
via activation of EGFR or ERBB2/3 signalling have
also been reported as mechanisms of escape from or
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resistance to FGFR inhibition in bladder tumor cell
lines [103, 115].
FGFR3 can interact with both p85, the negative
regulatory subunit of PI3K, via the PLC interaction
site Y762 [116] and TGF-activated kinase 1 (TAK1)
via amino acids 589–806 [117]. The consequences
of p85 interaction in urothelial cells have not been
studied but in the bladder cancer cell line MGH-U3,
which contains a Y375C mutation, FGFR3 signalling
via TAK1 was shown to positively regulate NF-κB
activity [117]. The juxtamembrane domain of FGFR3
has also been shown to interact with the N-terminal
region of the kinase domain of EphA4 leading to
mutual transactivation and ephrin-A1 potentiation of
the FGF response of wildtype FGFRs [118]. It has
also been shown that wildtype FGFRs 1–3 can form
all possible stable heterodimers in the absence of
ligand. Interestingly, largest effects were found for
heterodimers of mutant FGFR3 (G380R and A391E)
with wildtype FGFR3 [119]. These experiments were
carried out using ectopically-expressed proteins in
HEK293 and CHO cells and thus confirmation in
urothelial models is required. It will be of particularly
interest to examine the effects of common mutant
forms of FGFR3 found in bladder cancer in this
context.
Although S249C, Y375C and K652E mutant forms
are all able to activate both MAPK and PLC during
active proliferation of normal urothelial cells, only
S249C and Y375C forms show strong activation of
PLC at confluence. S249C with the PLC binding
site (amino acid Y762)[120] mutated to phenylala-
nine shows a major reduction in this response and in
continued proliferation and viability at confluence.
K652E fails to activate PLC and is unable to elicit
this phenotype [42]. This may indicate that there is
positive selection for mutant forms with this capa-
bility and explain the relatively infrequent finding of
K652E mutations in bladder tumors.
In urothelial and other cell types, FGFR3 fusions
activate MAPK signalling [46, 52, 121], but other
aspects of downstream signalling are likely to be
altered. The region of FGFR3 that is lost in these
fusions (amino acids 761–806) contains Y762, which
is implicated in PLC activation and binding of p85
[116], and part of the region implicated in interac-
tion with TAK1 [117]. As the fusions fail to activate
PLC, unlike point mutant forms, they are unable
to elicit the overgrowth of normal urothelial cells
at confluence [42, 46]. The consequences of altered
interaction of the fusion proteins with p85 and
TAK1 have not been examined.
ETV5, a member of the PEA subfamily of ETS
transcription factors [122] is an FGF effector during
embryonic development [123–125]. It is upregulated
and has been implicated in regulation of several
aspects of the malignant phenotype in other cancers
[126–130] and was identified as a pharmacodynamic
biomarker for inhibition of FGFRs 1–3 in a variety
of FGFR-driven tumor cell lines [131]. In normal
urothelial cells, ETV5 is upregulated downstream of
MAPK activation by ligand-stimulated wildtype or
point mutant forms of FGFR3, with S249C inducing
the highest level of upregulation. In these cells, ETV5
had an effect on confluent cell density independent
of FGFR3 expression, implicating it as an effec-
tor of this FGFR3-stimulated phenotype. In bladder
tumor cell lines, it conferred a proliferative advan-
tage and interestingly, in some MIBC-derived lines,
genes previously implicated in ETV5-induced EMT
in other tumour types were upregulated, implying a
context-dependent effect of FGFR3/ETV5 in these
cases [132].
In the FGFR3-driven tumor cell line 97-7, knock-
down of ETV5 was found to modulate expression
of WWTR1 (TAZ), and TAZ and its transcrip-
tional targets were also upregulated in TERT-NHUC
expressing mutant FGFR3 [132]. TAZ is a co-
transcriptional regulator that together with the
related protein YAP1 mediates transcription of pro-
proliferative and anti-apoptotic genes. YAP/TAZ are
negatively regulated through the Hippo pathway in
response to cell-cell contact and cell density. Thus
upregulation of TAZ as a consequence of FGFR3 sig-
nalling via ETV5 provides a rational explanation for
FGFR3-induced loss of contact inhibition.
Downstream effects of signalling by ectopically-
expressed wildtype FGFR3 and an FGFR3-TACC3
fusion have been examined using phosphoproteomics
and network analysis in TERT-NHUC in the pres-
ence and absence of FGF1 stimulation. Pathways
uniquely implicated by the fusion protein included
chaperone activation pathways and stress response.
Interestingly, two pathways related to TP53 expres-
sion and degradation were implicated and in both
TERT-NHUC and RT112 tumor cells it was shown
that TP53 is downregulated when FGFR3-TACC3
fusion and not wildtype FGFR3 is stimulated by
FGF1 [133].
Further information on downstream effects of
FGFR3-TACC3 has also come from examination of
expression changes elicited in astrocytes by the active
fusion protein or a kinase-dead version in the pres-
ence and absence of the FGFR inhibitor PD173074
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[134]. This revealed that FGFR3-TACC3 activates
genes involved in oxidative phosphorylation and
mitochondrial biogenesis. Cells expressing the fusion
showed increased oxygen consumption rate and mito-
chondrial inhibitors were shown to be inhibitory.
PIN4 was identified as a phosphorylation substrate
of FGFR3-TACC3 that triggered the biogenesis of
peroxisomes and the production of intracellular reac-
tive oxygen species (ROS) that in turn activated
the transcriptional coactivator PGCI, a regulator
of mitochondrial biogenesis [134]. Dependence of
tumors with FGFR3-TACC3 fusions on mitochon-
drial metabolism suggests that inhibitors of oxidative
phosphorylation may be beneficial for this subset of
patients. As this effect is driven by the kinase activity
of the fusion protein, it is possible that other fusions
and point mutant forms may have the same effect.
Whether these effects are relevant in the urothelial
context remains to be examined.
The ultimate effect of FGFR3 activation also
depends on a range of feedback regulatory mech-
anisms [135]. These include the sprouty proteins
(SPRY1-4) that are upregulated in response to FGFR
signalling and bind to GRB2 and SOS1 to provide
negative feedback [136] and SEF and DUSP pro-
teins. Changes in other key proteins such as FRS2,
or regulatory phosphatases [137, 138] may also have
major effects on signalling. Ultimately all of these
determine the context in which FGFR3 signals and
may require consideration in interpreting the results
of clinical trials of FGFR inhibitors.
FGFR3 ALTERATIONS AND BLADDER
CANCER SUBTYPES
Several classification systems based on mRNA
expression have been reported for bladder can-
cer. Most have focussed on MIBC [30, 88, 95,
139–141], one included two thirds NMIBC cases
[142] and one has focussed on NMIBC [143,
144]. Broad classification of MIBC into two sub-
types termed “luminal” and “basal-like”, showed
that FGFR3 mutation was confined to the lumi-
nal type [139]. Further sub-classification into three
[88], four [140] or more [30, 141] sub-groups has
confirmed that mutation and upregulated expres-
sion of FGFR3 are largely focussed in subgroups
of luminal tumors many of which have high levels
of expression of markers of urothelial differen-
tiation such as uroplakins, transcription factors
(TFs) involved in urothelial differentiation (PPARG,
FOXA1, GATA3, ELF3), ERBB2 and ERBB3.
Recent evaluation of both mRNA and protein expres-
sion by immunohistochemistry (IHC) has allowed
tumor cell phenotype to be determined indepen-
dent of the overall mRNA features of the entire
cellular population, and this defined 5 pheno-
typic classes of MIBC: urothelial-like, genomically
unstable, basal/SCC-like, mesenchymal-like, and
small-cell/neuroendocrine-like, with high FGFR3
expression within the urothelial-like group. This large
group could be further subdivided into UroA, UroB
and UroC, the latter two of which showed some
features in common with basal/SCC-like and GU
groups respectively [141]. An mRNA expression
classifier (LundTax), that captures these IHC and
RNA features was subsequently developed [95] and
used to examine the large TCGA MIBC dataset [30].
The UroA subtype, which is hypothesised to repre-
sent UroA NMIBC that have progressed, has high
frequency of FGFR3 mutations (44%), high expres-
sion of urothelial differentiation-associated TFs and
high expression of uroplakins. UroB also has a
high frequency of mutations (50%) but lacks expres-
sion of these TFs and markers of differentiation
and has upregulated expression of the basal-type
keratins KRT5 and KRT14 which are associated
with squamous differentiation. In contrast, Uro C
tumors contain few FGFR3 mutations (4%) and
lack a previously-derived FGFR3 signature [142],
but retain urothelial TFs and differentiation mark-
ers. This analysis reveals considerable heterogeneity
in the “luminal” class of MIBC that is reflected in
differential survival, with Uro A and UroC showing
significantly better outcome than UroB. Given the
high frequency of FGFR3 mutations in both UroA
and UroB, it will be of great interest to compare the
responses of these groups to FGFR inhibitors.
Three (1–3) [143] and more recently four (1, 2a,
2b and 3) transcriptional classes of NMIBC have
recently been described by the UROMOL group
[144]. Classes 1 and 3 contain mostly stage Ta tumors,
with relatively stable genomes measured by SNP
array analysis. These express high levels of FGFR3
and have a high frequency of FGFR3 mutation.
Fewest mutations were detected in class 2a, which
contained the largest proportion of T1 tumors and
showed significantly reduced recurrence-free sur-
vival.
Overall, the luminal/urothelial-like subtypes of
MIBC have relatively low levels of immune cell
infiltration and stromal markers. T-cell infiltration is
very low in FGFR3-mutant tumors [145] and this led
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to speculation that FGFR3 may be causally related
to poor infiltration and that such tumors may show
reduced response to immune checkpoint inhibitors.
Whether FGFR3 status directly influences the asso-
ciated non-infiltrated phenotype and response to
checkpoint inhibitors is under debate. During induc-
tion of tumors by BBN in a genetically engineered
mouse model expressing S249C in the urothelium,
no difference in T-cell infiltration compared to that in
wildtype mice was reported, though an early decrease
in neutrophil infiltration prior to the development of
tumors in S249C mice was evident [146]. Although
some initial studies reported that luminal phenotype
tumors responded less well to immune checkpoint
inhibitors [147, 148], analysis of response in direct
relationship to FGFR3 status in two large trials has
recently found no statistically significant relation-
ship. Data from this study suggests that stromal
TGF- signals, which are known to adversely influ-
ence response [149], are lower in FGFR3-altered
cases, potentially balancing out the effect of low T-
cell infiltration [150].
TIMING OF FGFR3 MUTATION AND
MUTATIONAL LANDSCAPE OF
FGFR3-ALTERED TUMORS
When does FGFR3 mutation occur during bladder
cancer pathogenesis? Although there is consider-
able information for NMIBC, the overall picture is
not completely clear and there are several caveats
that preclude straightforward interpretation of cur-
rent data. Common mutational events in NMIBC that
could represent initiating or very early events are
mutations in the TERT promoter [151, 152], FGFR3
mutation and loss of heterozygosity (LOH) of 9q
[153, 154], with mutation frequency in the order
TERT > FGFR3 >9q (∼80% >70% >50%). Does this
imply an order of events? One major caveat is that as
discussed above it is now clear that several molecular
subtypes of both NMIBC and MIBC exist and muta-
tional profiles and potentially the preferred order of
molecular events are also expected to differ.
One approach to investigate the timing of events
has been to examine frequency of events in cohorts
of samples that are predicted to represent “stages”
in disease pathogenesis. Several studies have been
made of morphologically “normal” urothelium from
patients with bladder cancer and potential precursor
lesions. Studies of histologically normal urothelium
from NMIBC-bearing bladders have found LOH of
9q or deletion detected by FISH [155–158], suggest-
ing that 9q deletion can precede the appearance of an
overt tumor. To date only a single study has examined
FGFR3 in such samples [159]. This study examined
normal samples from 38 patients with FGFR3-mutant
bladder tumors and found no mutations. 9q was not
examined, though it seems likely that a significant
number of the tumors would have had 9q LOH and
that, as in other studies, the surrounding “normal”
urothelium in such samples would contain some 9q
deletions. Studies of flat and papillary hyperplasia,
now defined as “urothelial proliferation of uncertain
malignant potential” [160], which may represent pre-
cursors of NMIBC, also report 9q LOH [161–163]
and in a single study that examined both FGFR3 and
9q, 9q LOH was found to be the more common event
[164]. These studies suggest that 9q LOH precedes
FGFR3 mutation, at least in a subset of NMIBC.
However, there may be different requirements and
timing of events in different NMIBC subtypes. Thus,
it is noteworthy that two studies aimed at defining
molecular subtypes of NMIBC have described one
group of low-grade tumors with FGFR3 mutation but
retention of 9q and a second with both FGFR3 muta-
tion and 9q LOH [77, 165]. This indicates that the
ordering of these so-called “early” events is not uni-
form, and points to two distinct subsets of tumors,
only one with 9q loss as an early event but both with
common FGFR3 mutation.
As indicated above, downregulation of miRs
99/100 and upregulation of FGFR3 may precede
acquisition of mutations [92]. Compatible with this
suggestion is the finding that a germline sequence
variant close to FGFR3 is associated with low-grade
and low-stage bladder cancer. This variant, at least in
adipose tissue, is associated with increased FGFR3
expression and importantly, the frequency of the vari-
ant is higher in FGFR3-mutant tumors [166].
Urothelial papilloma and inverted urothelial papil-
loma are low-grade tumors with low frequency of
recurrence, often occurring in young patients, and
with debated relationship to urothelial carcinoma.
In many of these cases, FGFR3 mutation is absent,
with a high frequency of HRAS or KRAS mutations
[167–169], indicating a separate molecular profile
from both PUNLMP and low-grade non-invasive
urothelial carcinoma for this benign lesion.
In flat dysplasia and carcinoma in situ (CIS) that are
predicted precursors of non-papillary MIBC, TP53
mutation/17p LOH and 9q LOH are common, but
FGFR3 mutations are absent [170, 171], indicating
that FGFR3 has no early role in the development
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of these tumors. TP53 mutations and/or upregulated
expression are detected frequently in flat dysplasia
and CIS [171–173] and appear to precede deletion of
chromosome 9 [171, 174].
The distinct mutational profiles of NMIBC and
MIBC and their precursor lesions provided evi-
dence for the early concept that bladder tumor
development may follow two distinct pathways, the
non-invasive/papillary pathway with FGFR3 alter-
ations as a major feature and the pathway initiated
in CIS, containing many TP53 mutations [171–173].
This concept remains, and in general is supported
by more profound current understanding of tumors
of both types. However, it now seems clear that
papillary/luminal/urothelial-like MIBC with FGFR3
alteration as a major feature represent NMIBC that
have progressed. Several studies indicate that loss
of the 9p21 locus CDKN2A, which encodes the
RB1 and TP53 regulators p16INK4A and p14ARF,
may allow progression of FGFR3-mutant NMIBC.
p16INK4A is a regulator of cell cycle arrest and senes-
cence via binding to CDK4/6, which retains the
retinoblastoma protein RB1 in a hypophosphory-
lated and active state. It is upregulated in response
to various oncogenic stimuli, inducing a state termed
“oncogene-induced senescence” [175], and in the set-
ting of an FGFR3 mutation may be partially induced
and restrain tumor growth. CDKN2A homozygous
deletion is found more frequently in FGFR3-mutant
tumors [30, 95, 176] and strikingly, this was found
in 79% of FGFR3-mutant MIBC [176]. The role of
CKDN2A/RB1 inactivation in FGFR3-mutant tumor
pathogenesis has also been indicated in a genetically-
engineered mouse model with inducible expression
of Fgfr-S243C (mouse equivalent of human S249C)
in the urothelium. Although increased levels of p-
AKT and p-MAPK were induced, there was no
increase in urothelial proliferation and p16, p19
and p53 protein levels increased. However, when
crossed with mice with urothelial expression of
SV40T, which inactivates both p53 and Rb1, high-
grade papillary tumors developed [177]. Thus, loss
of CDKN2A/RB1-regulated cell cycle arrest and/or
the oncogene-induced senescence function appears
essential in allowing tumor formation in the Fgfr3-
driven mouse model and for tumor progression in
human NMIBC. This has important implications for
follow-up of FGFR3-mutant NMIBC with deletion of
CDKN2A, as these may represent a high-risk group.
Examination of the TCGA data supports this con-
cept. Separation of MIBC based on CDKN2A deletion
status reveals that FGFR3 mutation is more com-
mon in samples with deletion, compatible with this
predominantly luminal-papillary subtype tumors rep-
resenting progressed NMIBC. These tumors also
contain a higher frequency of mutations that are com-
mon in NMIBC such as PIK3CA and STAG2. TP53
mutation is more common in tumors with reten-
tion of CDKN2A that lack FGFR3 mutation and is
skewed towards the basal-squamous and other sub-
types (Fig. 3A).
An alternative mechanism of progression for
FGFR3-mutant tumors is suggested by studies that
have shown the presence of mutation in a non-
invasive/superficial part of a tumor and lack of
mutation in a deeper or invasive component [17, 62].
It is possible that cases with discordant mutation
status contain more than one tumor clone but alterna-
tively, loss of FGFR3 mutation may have occurred,
potentially alleviating oncogene-induced upregula-
tion of p16 and related cell cycle checkpoint genes
and allowing tumor progression.
Where does mutation of the TERT promoter fit
within these pathogenesis pathways? Such mutations
are more common than FGFR3 mutation in NMIBC
and have been reported in the “normal” urothelium
of tumor-bearing bladders [178] and in urine sam-
ples up to 10 years before diagnosis of bladder cancer
[179]. As mutations are equally common in NMIBC
and MIBC (70–80%), these mutations may precede
all other molecular events identified to date and rep-
resent an essential and potentially initiating event.
Telomerase is known to allow cells to overcome
oncogene-induced senescence [180] and thus early
mutation may allow cellular tolerance of later FGFR3
mutations.
Recent findings suggest potential complex inter-
play between FGFR3 and several other genes early
in NMIBC pathogenesis. In thyroid cancer, ETV5 is
upregulated downstream of mutant BRAF and binds
to the TERT promoter [181]. Interestingly, binding
is preferentially to the –124 bp(T) TERT promoter
mutation that is the most common mutation found
in both thyroid and bladder tumors [182]. It is also
known that MYC can activate TERT [183] and recent
data show that ETV5 and MYC can cooperate in de-
repressing the TERT promoter [184]. Taken together,
this could indicate a perfect storm between TERT,
FGFR3, ETV5, MYC and TAZ early in bladder can-
cer pathogenesis with FGFR3 mutation playing a
central role (Fig. 4).
What is the final mutational context of FGFR3-
altered tumors? FGFR3 alterations are generally
found in genomically stable tumors with low muta-
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Fig. 3. Oncoplots showing distribution of common mutations according to chromosome 9 status. A. Oncoplot for selected genes in muscle-
invasive bladder tumours with and without deletion of the CDKN2A locus. Data from [30]. B. Oncoplot for selected genes in stage Ta tumors
with and without 9q loss. Data from [165].
Fig. 4. Hypothetical pathways of pathogenesis of non-invasive and
invasive bladder cancer. Straight arrows show potential timing of
selected events during development of NMIBC and MIBC based
on data from dysplasia, CIS and urothelial hyperplasia and sub-
type analysis of NMIBC and MIBC. FGFR3, PIK3CA: activating
point mutation. TERT: promoter point mutation. TP53: inactivat-
ing mutation. HD: homozygous deletion. Curved arrows indicate
interrelated regulation of expression of FGFR3, TERT, MYC,
ETV5 and TAZ.
tional burden. When examined across the entire
bladder cancer spectrum, mutations in FGFR3 and
TP53 mutation are almost mutually exclusive [27,
185–188]. Similarly, few FGFR3-altered tumors have
mutations in RB1, PTEN or high-level amplification
of E2F3 [30], all features of non-luminal MIBC. As
indicated above, FGFR3 and RAS gene mutations
are mutually exclusive [112] and FGFR3 and ERBB2
mutations are reported to be mutually exclusive in
high-grade NMIBC [29].
Common features accompanying FGFR3 mutation
in stage Ta tumors are mutations in PIK3CA, KDM6A
and STAG2 [165]. When the mutational profiles of
Ta tumors with and without loss of 9q are examined,
both groups have high frequency of FGFR3 muta-
tion (Fig. 3B), but interestingly, those with no loss of
9q have a greater number of RAS gene mutations
and a higher frequency of STAG2 mutation [165].
It is assumed that, as tumors with 9q LOH usually
have hemizygous deletion of the entire chromosome,
this group contains those at risk of progression to
MIBC via loss of the second allele of CDKN2A. How
these different mutational constellations contribute to
phenotype and whether this affects clinical outcome
remains to be evaluated. Larger studies of NMIBC
including methylation and non-coding RNA profiles
may elucidate exact requirements and interrelation-
ships more fully in the future. However, it is clear
that in Ta tumors mutations in PIK3CA almost invari-
ably occur in tumors with FGFR3 or RAS mutation
[113, 165, 189–192] (Fig. 3B). Why PIK3CA muta-
tion in the absence of FGFR3 mutation is common
in MIBC (Fig. 3A) but not found in NMIBC remains
an unanswered question.
PROGNOSTIC AND PREDICTIVE VALUE
OF FGFR3 ALTERATIONS
As FGFR3 point mutations are most common in
tumors of low grade and stage, there is a strong
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relationship of these mutations with good clinical
outcome. Several studies have examined the relation-
ship of point mutation or FGFR3 protein expression
to recurrence in NMIBC and most report no signif-
icant relationship [59, 186, 193–195], though when
Ta tumors were stratified by grade, an association
was reported in TaG1 tumors only [24]. In univari-
ate analysis of data from all NMIBC (Ta and T1),
FGFR3 wildtype or tumors expressing low levels
of FGFR3 protein have higher risk of progression,
though this has not been found to be an indepen-
dent prognostic factor in multivariate analyses [59,
194, 195]. In the subset of FGFR3-mutant tumors,
hemizygous or homozygous deletion of the CDKN2A
locus is a predictor of progression that is indepen-
dent of tumor grade and stage [176]. When FGFR3
mutation is assessed in combination with MIB-1
expression as a measure of proliferative index this
“molecular grade” showed independent significance
with FGFR3 mutant, MIB-1 low tumors having
best outcome. When used with EORTC risk score
[196], this provided improved prediction of progres-
sion [195]. When primary T1 tumors alone were
evaluated, a significant association of FGFR3 muta-
tion or expression status with disease progression
has been reported in multivariate analysis in some
[197, 198] but not all studies [27]. Overall, these
data indicate that FGFR3 mutation identifies patients
with favourable NMIBC disease, though only grade
and stage remain single independent predictors of
outcome.
In a very large cohort of patients with MIBC
or high-risk NMIBC that were treated with rad-
ical cystectomy, mutation was related to longer
disease-specific survival [63]. Interestingly, although
over-expression of wildtype protein was associated
with lower tumor stage and grade, it was not associ-
ated with outcome, potentially indicating a functional
distinction between mutation and over-expression
of wildtype FGFR3, with a driver role for mutant
FGFR3, and possibly a passenger role only for upreg-
ulated expression of wildtype protein. This provides
additional evidence that FGFR3 mutation rather than
upregulated expression may represent the better pre-
dictive biomarker for FGFR inhibitor therapies. A
response rate to the FGFR inhibitor Erdafitinib of
40% has been reported in patients whose tumors con-
tained FGFR3 point mutations or FGFR2/3 fusions
[199] leading to FDA approval for this drug in locally
advanced or metastatic bladder cancer. Whilst this
response rate is very encouraging, it will be impor-
tant to explain the lack of response in the remaining
60% of patients. Although inhibition of FGFR3 in cell
lines with mutation has been widely demonstrated,
as discussed above, it is clear that several mecha-
nisms allow escape from inhibition or development
of stable resistance. Detailed discussion is beyond
the scope of this review but it will be important
to understand these mechanisms if FGFR inhibitors
are to be applied appropriately and relevant com-
bination therapies developed in the future. Lack of
response may also indicate loss of dependence on
FGFR3 during tumor progression or intratumor het-
erogeneity with outgrowth of a non-addicted variant
in these advanced tumors. It is hypothesised that het-
erogeneity and cellular signalling plasticity may be
much less prominent in low-grade NMIBC. Thus
FGFR3 as a therapeutic target may be more relevant
in these patients if localised means of targeting can be
developed.
The significance of FGFR3 status in predicting
response to chemotherapy has not yet been exam-
ined extensively. As previous studies have indicated
that better response to cisplatin-based chemotherapy
is associated with basal rather than luminal expres-
sion subtype [200, 201], worse response of FGFR3
mutant tumors might be expected as mutations and
upregulated expression of FGFR3 are far more com-
mon in the luminal subtype. Findings to date suggest
that this is the case. One study that evaluated FGFR3
mutation status and protein expression in 72 MIBC
patients, 42 of whom were treated with adjuvant
chemotherapy, reported significantly shorter overall
survival and borderline significance for disease-
free survival related to FGFR3 overexpression. This
remained a significant independent prognostic factor
in multivariate analysis. The relationship to muta-
tion was not significant, but few samples in the
chemotherapy group contained mutation [202]. A
recent retrospective study that examined three groups
of patients treated with cisplatin-based chemother-
apy supports these findings. Lower rates of pathologic
response to neoadjuvant chemotherapy and reduced
recurrence-free survival were recorded in patients
whose tumors contained FGFR3 point mutations or
fusions. In patients included in the TCGA study of
MIBC who received adjuvant chemotherapy reduced
RFS was also found in FGFR3 altered tumors.
In a third group of metastatic patients treated
with first line platinum-based chemotherapy FGFR3
alteration was associated with a different pattern
of metastatic spread including higher rates of pul-
monary metastases and with lower response rate.
Patients with FGFR3-altered tumors that did not
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receive chemotherapy had superior clinical outcome
[203]. Overall this suggests that despite the relation-
ship of FGFR3 status to better outcome in MIBC,
chemotherapy may be detrimental to this group
and that other treatment options including FGFR
inhibitor therapy may be more suitable. Interest-
ingly, an in vitro study has also reported decreased
sensitivity to cisplatin of a bladder tumor cell line
(97-7) containing an S249C mutation compared to
wildtype cell lines. In this case, a high level of
p-AKT in the mutant line was decreased follow-
ing FGFR3 inhibition and this was associated with
increased cisplatin sensitivity [204]. Larger studies
of patients treated with cisplatin-based neoadjuvant
chemotherapy in combination with molecular pro-
filing may allow the basis for these effects to be
elucidated.
CONCLUSIONS
Whilst a great deal has been learnt about FGFR3
and its role in the pathogenesis of NMIBC and
MIBC, much remains to be clarified if it is to be
optimally targeted in these settings. Current data
suggests that it is an early event in NMIBC, though
we lack understanding of exactly how it contributes
during the initial development of urothelial hyper-
plasia and the elicitation of a branching vasculature
and papillary tumor architecture. More detailed
analyses of these early stages and the development
of mechanisms for localised FGFR3 targeting or
targeting of the FGFR3-related phenotype have
potential for major impact on the clinical manage-
ment of the very large NMIBC population. In vitro
and in vivo models may make a major contribution
to understanding these early processes and more
complex models may improve understanding of any
influences of FGFR3 signalling on tumor infiltration.
Unlike other epithelial tissues, the ability to culture
normal urothelial cells with relative ease is a major
advantage and this should allow the hypothetical
interactions of TERT, FGFR3 and MYC in NMIBC
pathogenesis hypothesised here to be tested. In
MIBC, the excitement related to responses to FGFR
inhibitors is tempered by lack of good predictive
biomarkers. More detailed molecular profiling that
takes into account some of the broader mecha-
nisms of FGFR3 regulation and cross-talk should
facilitate improved biomarker-driven treatment
selection.
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